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In  connection with  the  study of the  use  of  concentrated  refined 
antibody preparations in the treatment of pneumonia  due to Types 
I, H  and III it seemed desirable to study the possibility of treating 
pneumonia  cases  due  to  pneumococci  of  the  miscellaneous  types 
hitherto  classified  as  Group  IV.  In  general,  clinical  results  have 
indicated that these cases are benefited very little by treatment with 
the  therapeutic  antibody  preparations  now  in  use.  Furthermore, 
since some cases due to these organisms are severe and a  considerable 
percentage develop septicemia it seems worth while to try to find a 
suitable serum therapy for them. 
The classification  of pneumococci  into Types I, II and III and Group IV is 
generally known and accepted.  Other types have been differentiated, but the 
group'.lng has not been generally utilized,  probably due to the absence of  diag- 
nostic or therapeutic serum suitable for use with  the new types and to the belief 
that the types did not occur in lobar pneumonia with sufficient  frequency  to 
warrant attention.  Lister (1)  found another type more  prevalent  than  Types 
I, II and III in South Africa.  Olmstead  (2)  in a study of 213 strains by direct 
agglutination found that the miscellaneous  strains which  she studied could  be 
classified in twelve groups.  Clough  (3)  classified 94  strains  in twelve groups. 
Strains giving delayed or incomplete but marked agglutination  with Type II 
serum were classified by Avery (4) as Subgroup II strains and separated by agglu- 
* This investigation was aided by grants of money from the New York Univer- 
sity Littauer Pneumonia Fund and the  Metropolitan Life Insurance Influenza 
Cornm~ssion Fund for part of the expense. 
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tination and protection tests into Subgroup II A and  Subgroup IIB.  Stillman 
(5)  described further  Subgroup II strains  on the basis of agglutination  tests. 
Among 55 strains  isolated during the influenza epidemic, we (6)  differentiated 
nineteen types which represented four small groups and thirteen unrelated strains. 
Griffith, (7) studying forty-nine strains not  Types I, II or III from respiratory 
diseases, thirty-four of which were from lobar pneumonia, distinguished  twelve 
serological types.  He found that strains corresponding to the Sub II A and  Sub 
IIB of Avery predominated.  Robinson (8)found eight groups among 65 strains 
of the so called Group IV.  One group was identified as the cause of an epidemic. 
Sugg, Gaspari, Fleming and Neill, (9) and Harris, Sugg and Neill (10) described 
a group of strains which were immunologically related to Type III. 
In  the present  investigation  it was necessary, preliminary  to  the 
selection of suitable  strains  for the production  of therapeutic serum, 
again to find into what types the miscellaneous strains were divisible 
and which types were most prevalent.  The majority of the strains I 
were isolated  at  the  Harlem  Hospital;  a  smaller  number  2 from  the 
Bellevue Hospital.  120 strains from lobar pneumonia cases which did 
not  agglutinate  or reacted atypically with  diagnostic antiserums  for 
Types I,  II and  III,  were studied.  Strains  of Subgroups II A  and 
II B were obtained from Dr. Avery at the beginning of the investiga- 
tion; and later, in order to learn something concerning the distribution 
of the types, strains were obtained from Dr. Robinson representative 
of the types found in t'ittsburg,  also a  strain  of a  non-typical Type 
III from Dr. Sugg of Nashville, Tennessee.  Antiserums for five of the 
types found in  England  were sent us by Dr.  Griffith.  Monovalent 
antiserums  were prepared  and  agglutination  tests  carried  out.  By 
direct  agglutination  tests,  the  120  case strains  studied were divided 
into ten  groups  containing  four  or more  strains  each, one  groap  of 
only two strains,  and  two strains  differing from each other and from 
the preceding types, and a  miscellaneous group differing from all the 
preceding  types and  among  which further  types were not  separable 
with the antiserums thus far prepared.  It is apparent that additional 
agglutinating  antiserums might divide the  group  of undifferentiated 
strains  thus  adding  to  the  number  of  types.  The  search  for  new 
types is to be continued.  We are designating  the ten  types having 
1  We are indebted to Miss Dedrlck, Miss Brown and  MissGideon for  these 
cultures. 
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four or more strains by Roman numerals from Type IV to Type XIII. 
The agglutination results with representative strains of each type and 
antiserums prepared for each type are given in Table I.  Only a small 
amount  of  cross-reaction  occurred  among  the  types.  When  rabbit 
antiserums  are  employed  this is usually  the  case;  generally  there is 
more cross-reaction when horse antiserums are used. 
Each group of strains was studied in regard to the ability of repre- 
sentative strains to stimulate the production of protective antibodies. 
TABLE  I. 
The Agglutination Titer of the Antiserums  for Representative Strains of Each of the 
Recently Separated Types with the Homologous  Strains and Strains of 
Each of the Other Types. 
Type antiserums 
Type strains 
IV 
V 
VI 
VII 
VIII 
IX 
X 
XI 
XII 
XIII 
IV 
1-540 
1-10 
1-5 
1-320 
1-40 
1-20 
1-5 
VI 
1-150 
1-5 
VII 
1-20 
1-20 
1-640 
1-40 
1-20 
1-20 
VIII  IX 
.  --  .  1-20.  --  • 
--  i-5 
1-640  1-20 
--  1-64C 
1-40  1-20 
--  i-5 
--  1-5 
x  xI 
1-5 
1-20  -- 
I-5  -- 
1-640  -- 
--  1-320 
i-5 
XII 
q 
1-160 
XIH 
N 
1-160 
* Indicates that no agglutination was found in dilutions as low as 1-5. 
The power of antiserums produced by injection of a  single strain  to 
protect against freshly isolated as well as old strains belonging to the 
same type, was determined.  The amount of cross-protection of anti- 
serums for one type  against  strains of other types was studied  also. 
Antiserums  for  at  least  two  strains  of  each  type  were  prepared. 
Cultural  or  morphological  peculiarities  of  the  strains  were  noted. 
The special data are given in detail in  a  discussion of each group of 
strains. 
Type IV.--Twenty-one strains are of th:s type, nineteen were from 
recent cases and two were stock strains.  One of the stock strains is 
an "antitoxin"  strain from the Lilly Laboratories,  the other a  repre- 464  PNELr~OCOCCI GROUP IV 
sentative of one of the groups, "Group IV B," obtained from Robinson. 
Of the nineteen  cases due to this type, sixteen were rated  3 as severe 
and  seven  of  these  died;  three  were  rated  as  mild.  Four  of  the 
patients who died and one who recovered had positive blood cultures. 
The strains of Type IV had a peculiarly high virulence for mice, all 
being fully virulent when first tested and remaining so throughout the 
TABLE  II. 
Protection Tests Showing the Comparative Protection of a Polyvalent Type I, H  and 
III  Concentrated Antibody  Preparation  and  of an Antiserum for  Type IV 
against a Type IV Culture. 
Polyvalent Types I, II 
Antiserum amounts 
0.1 
0.05 
0.02 
0.01 
0.005 
Control 
of virulence 
of culture 
III antibody preparation 
Results in mice 
+48 hrs. 
+24 hrs. 
+48 hrs. 
+24 hrs. 
+48 hrs. 
Amount 
0.000001 
0.0000001 
0.00000001 
Monovalent Type IV antiserum (rabbit) 
Antiserum amounts 
0.001 
0.0005 
0.0002 
0.0001 
0.00005 
0.00002 
Colony count 
153 
16 
2 
Results in mice 
Survived 
Survived 
Survived 
+48 hrs. 
+48 hrs. 
+30 hrs. 
Results in mlce 
+48 hrs. 
+48 hrs. 
+48 hrs. 
Method: 0.001 cc. of culture (0.5 cc. of dilution 1-500 in broth) and the desired 
amount of serum diluted with saline  (0.5 cc. of required dilution) was drawn into 
a syringe and injected intraperitoneally into mice. 
Control: 0.5  cc. of the dilution made in broth containing the required amount 
of culture and 0.5 cc. broth was drawn into a syringe and injected into mice. 
The approximate number of diplococci injected were estimated by colony count 
of blood agar poured plates. 
period of the  investigation.  By  fully virulent  we mean  that  ten  or 
fewer  diplococci  killed  mice  in  less  than  48  hours.  This  dose  was 
usually contained in 0.00000001  cc. of 18 hour broth culture as shown 
by  colony  count  in  poured  blood  agar plates.  In order  to  test  the 
s We are indebted to Dr. Bullowa and Dr. Rosenbluth for the ratings made in 
the clinical investigation of pneumonia at the Harlem Hospital and to Dr.  Sutliff 
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potency of antibody stimulated by injection of this type,  an  anti- 
serum from a rabbit inoculated for 5 weeks with a representative strain 
was tested to determine its protective value against the strain injected 
and fifteen other strains classified in this group.  The results indicated 
100  to  500  protective  units  4 against  each  strain.  The  remaining 
strains were not tested. 
The protective value of a trivalent Type I, II and III concentrated 
antibody preparation having  1500  protective units against Type I, 
1000  against Type II  and 20  against Type III was  tested against 
Type IV.  This preparation had less than one unit per cc. of protection 
for Type IV, whereas the control homologous antiserum (rabbit)  had 
500 units of protection per cc.  The results of these tests are shown 
in Table II.  Monovalent antibody preparations for Type I, for Type 
II and for Type III and other trivalent antibody preparations than 
the one mentioned above were tried with similar results.  It is ap- 
parent that  the antibody preparations for Types I,  II and III are 
practically  useless  for  treatment  of  Type  IV  infections  and  that 
antibody preparations  to  be  efficient must be  homologous to  this 
type.  With this in view the immunization of horses with a Type IV 
strain was begun.  After 21 weeks of injections the antiserum from a 
horse had  100 protective units per cc.  being suitable for diagnostic 
and experimental therapeutic use. 
It is interesting that our Type IV corresponds with one of the types, 
"Pn. 10," found by  Griffith in  England.  His  strains were isolated 
from three  cases of lobar Pneumonia  , one of bronchopneumonia and 
one  of  acute  bronchitis.  Our  Type  IV  also  corresponds with  the 
"Group IV B" differentiated by Robinson in Pittsburg which included 
six strains from lobar pneumonia with a case mortality of 33 per cent. 
Considering the limited number of cases in both series the mortality 
figure closely approaches ours of 37 per cent.  Because of its apparent 
wide distribution and its virulence it  is  expected that this type will 
prove to be of especial importance. 
Type V.--Six strains from cases are included in this group and two 
stock strains, the Subgroup II A strain of Avery and a strain of Group 
IV E  of Robinson.  All the pneumonia cases due to this type were 
4 A unit is ten times the smallest amount of serum which protects mice against 
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especially severe.  Five out of six of the patients were shown to have 
positive blood cultures and these cases died. 
All  the  strains  examined  of this  group  when  cultivated  in  blood 
broth media  showed a  tendency to hemolyze blood cells; with  some 
strains  the tendency was very much more marked  than  with others 
TABLE  III. 
Protection Tests Showing the Comparative Degree of Protection of a Type II Con- 
centrated Antibody _Preparation and of a Type V Antiserum against a Type V 
and a Type II Strain. 
Protection  against  Type V  Protection  against  Type II 
Monovolent Type V  Monovalent Type V 
Type II antibody  antiserum (rabbit)  Type n  antibody  antiserum (rabbit) 
Control 
of virulence 
of culture 
~  ~.~ 
.~ o  ~ 
0.02  Survived 
0.01  Survived 
0.005  +96 hrs. 
0.002  +30 hrs. 
0.001  +48 hrs. 
0.0005  +48 hrs. 
Amount 
C~. 
0.000001 
0.0000001 
0.00000001 
~m 
~'~  ~.~ 
.~g  -~e 
0.002  Survived 
0.001  Survived 
0.0005  +48 hrs. 
0.0002  +48 hrs. 
0.0001  +48 hrs. 
Colony  Results in 
count  mice 
144  +48 hrs. 
12  +48 hrs. 
2  +48 hrs. 
~  ~'~ 
CC. 
0.0002  Survived 
O. 0001  Survived 
0.00005  Survived 
0.00002  +72 hrs. 
0.00001  +48 hrs. 
Amount 
co. 
Control  0.000001 
of  virulence  ]0.0000001 
of  culture  0.00000001 
~  ~.~ 
~.~ 
Cg, 
0.  I  +22 hrs. 
0.05  +46 hrs. 
0.02  +46 hrs. 
0.01  +52 hrs. 
0.005  +46 hrs. 
0.002  +22 hrs. 
Colony  Results  iu 
count  mice 
120  +48 hrs. 
12  +48 hrs. 
3  +48 hrs. 
* 0.001 cc. of 18 hour broth culture was injected with the different amounts of 
antiserum. 
Method:  See foot-notes to Table II. 
but  in  general  it was greater  than that  of the other pneumococcus 
cultures studied.  This ability to produce hemolytic substances may 
account for the  severity of the  septicemic cases.  The  strains  when 
first isolated from patients were all highly virulent for mice, but did not 
hold  their  virulence  as  well  as  the  strains  of  Type IV.  After  the 
virulence had fallen attempts to raise the virulence sufficiently high to 
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As noted above the Subgroup II A of Avery is of this type.  Avery 
found that the strains were agglutinated to a  considerable degree in 
Type II serum although the agglutination was usually delayed and 
often incomplete.  He also found that Type II antiserum protected 
to some extent against Subgroup II A  cultures while antiserum for 
Subgroup II A failed to protect against Type II cultures.  Our results 
have been similar to his. 
In order to find whether the therapeutic preparations, now avail- 
able, were potent  against infection with this  type, protection tests 
were carried out using polyvalent antibody preparations for Types I, 
II and III, and monovalent antibody preparations for Type I, for 
Type II and for Type III.  The Type II antibody preparation having 
2000 units against Type II had only 10 to 20 units per cc. against the 
Type V strain.  The polyvalent antibody preparations also had 10 to 
20 protective units per cc. against Type V strains.  Type I and Type 
III antibody had less than 1 unit per cc. against Type V.  Compara- 
tive tests with the serum of a  rabbit immunized against a  Type V 
strain and with Type II antibody are shown in Table IH.  The rabbit 
serum for the Type V strain had 100 units of protection per cc.  It is 
evident that a preparation containing 10 to 20 units per cc. would be of 
little value as compared with one containing 100 units per cc. or more. 
Neither the polyvaient antibody preparations for Types I, II and III 
nor  the  Type  II  antiserum  is  suitable  for  therapeutic use  against 
infections with this  type.  Since diagnosis and treatment must be 
carried out independently of Type II we have thought it better to give 
the type an entirely distinct designation to avoid confusion.  Potent 
antiserum for determining the type and for therapeutic use has  been 
obtained by inoculation of horses. 
Griflith found this type second in prevalence among the types into 
which  he separated Group IV.  Robinson found this type, termed by him 
"Group IV E," most numerous during the winter of 1928 in Pittsburg. 5 
On account of its prevalence, virulence and special tendency to infect 
the blood stream, this type should be of especial interest for serum 
treatment. 
Type VI.--Seven strains from pneumonia cases are included in this 
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group, also one stock strain, the Subgroup II B  strain of Avery.  Of 
the seven patients two had positive blood cultures and died.  Three 
of  the  cases were rated  as  moderate in  severity and  two  as mild. 
The case strains of this type were generally of somewhat lower viru- 
lence for mice than those of Types IV and V.  Those which were viru- 
lent when isolated had a tendency to lose their virulence very rapidly. 
Type VI strains hemolyzed blood less actively than Type V but more 
actively  than  the  majority  of  the  other  pneumococcus  cultures 
studied.  The strains of Type VI are similar to these termed Sub IIB 
by Avery.  He found the relationship of this type similar to that of 
the Subgroup II A strains to Type II.  He found that Subgroup IIB 
was immunologically distinct from Subgroup II A.  Our results were 
similar.  We found that monovalent or polyvalent preparations which 
were highly protective against Type II would protect against Type 
VI to a slightly greater degree than against Type V.  However, pro- 
tection to  a  high degree was obtained with antiserums prepared by 
injections  of  Type  VI  strains.  The  largest  group  separated  by 
Griffith from the so called Group IV corresponded with our Type VI. 
He found it next in prevalence to Types I and II. 
The  data  available  indicate  that  infections  with  this  type  are 
milder than with Types IV or V and it may be expected that cases will 
respond more readily to treatment. 
Type  VIA---Eleven  strains from cases of pneumonia were of this 
type.  Seven cases were rated as severe and two of these died.  Two 
cases were moderate in severity.  No data were available in regard to 
the ratings of the other two cases.  One of the fatal cases and one 
case which recovered had positive blood cultures. 
The strains  of Type VII were generally of  low virulence for mice. 
None were suitable as test strains for carrying out protection tests as 
the virulence could not be raised.  Therefore the protective value of 
a  therapeutic antiserum (horse) prepared for this type could not be 
accurately determined by  the mouse protection method.  Possibly 
another method may be devised.  This antiserum is suitable, however, 
for determining the presence of this type. 
Type VIII.--Four strains from cases and two stock strains are of 
this type.  Of the stock strains one is a representative of the "Group 
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Of  the  four  cases  three  were  rated  as  severe and  one  as  moderate. 
One patient who had a positive blood culture died. 
The  Type  VIII  strains  were  found  to  agglutinate  in  Type  III 
antiserum to a  marked degree but less than typical Type III strains, 
TABLE  IV. 
Protection Tests  Showing  the  Comparative Degree of  Protection of  Moneoalent 
Antiserums for Type IH and Type VIII against a Type III and a Type VIII 
Strain. 
J 
Protection  against  Type  VIII 
Type IH anti.urn  (rabbit) 
i' 
CC. 
0.1  -I-27 hrs. 
0.05  -I-22 hrs. 
0.02  +22 hrs. 
0.01  +27 hrs. 
0.005  +45 hrs. 
0.002  +27 hrs. 
Amount 
Control  0.000001 
of vim-  0.0000001 
lence 
of culture  0.00000001 
I' 
Type VIII antiserum  Type III antiserum 
(rabbit)  (rabbit) 
0.001 
0.0005 
0.0002 
0.0001 
0.0000~ 
Colony 
count 
214 
34 
Protection against  Type IH 
~  .  o 
~° 
Survived  0.002 
Survived  0.001 
+78 hrs.  0.0005 
+45 hrs.  0.0002 
+22 hrs.  0.0001 
Results in 
mice 
+27 hrs.  Control 
+45 hrs.  of viru- 
lence 
+72 hrs.  of culture 
Survived 
Survived 
+45 hrs. 
+45 hrs. 
+27 hrs. 
Amount 
~° 
0.000001 
0.0000001 
0.00000001 
Type VIII antiserum 
(rabbit) 
ii  i:! 
~. 
0.1  Survived 
0.05  Survived 
0.02  Survived 
0.01  +45 hrs. 
0.005  +45 hrs. 
0.002  +23 hrs. 
Colony  Results in 
oount  mice 
163  +48 hrs. 
24  +48 hrs. 
1  Survived 
* 0.001 cc. of 18 hour broth culture was injected with the different amounts of 
antiserum. 
Meihod: See foot-notes to Table II. 
this would lead to confusion of the more reactive of these strains with 
Type III in routine "typing" tests.  Two strains of Type VIII were 
sent us'from a  hospital in response to our request for freshly isolated 
Type III cultures.  It is impossible, at present, to judge the prevalence 
of this type, as other strains belonging to it may have been classified 
as  Type  III  in  the  routine  hospital  tests.  We  were  receiving  the 470  PNEUMOCOCCI  GROUP  IV 
strains which apparently did not fall with Types I, II and III.  We 
are planning to study all the presumed Type III strains isolated during 
the coming season and will then have more definite information on 
this point. 
Protection tests were carried out with monovalent rabbit antiserum 
for Type VIII and for Type III.  The results with the monovalent 
rabbit  antiserums are  given in  Table  IV.  The  antiserum for  the 
Type VIII strain had 500 protective units per cc. against Type VIII 
strains (four strains tested), but only 20 units per cc. against a stock 
Type III strain and 1 unit against a freshly isolated Type III strain. 
An antiserum for a stock Type III strain had 100 protective units per 
cc. against the stock Type III strain, 25 units against a freshly isolated 
Type III strain and less than 1 unit per cc. against Type VIII strains. 
The most potent Type III concentrated antibody available had only 
1  to 2 protective units" or less against Type VIII strains.  Polyvalent 
antibody for Types I, II and III failed to protect. 
A very interesting and detailed study of this type has been published 
recently by Sugg, Gaspari,  Fleming and Nell1, and by Harris,  Sugg 
and Neill.  Our findings agree in general with theirs.  The "Group 
IV A" of Robinson corresponding to this type, was one of the three 
types of miscellaneous pneumococci found most prevalent in Pittsburg 
during the  winter of  1927.  The mortality among his cases was  14 
per cent. 
The differentiation of this type from Type III is very important in 
the investigation of  the use  of  antibody preparations in  Type III 
cases.  At least some part, even if small, of the failure with Type III 
antibody treatment is probably due to the failure to exclude cases due 
to this type.  We hope that in the future this type may be identified 
and we are preparing a specific antiserum for therapy. 
Type  IX.--Six  strains  from  pneumonia cases  are  of  this  type. 
One of the cases was rated as severe, four as moderate, one as mild. 
One patient who had a positive blood culture died.  All strains were of 
comparatively low virulence for mice when tested.  Perhaps this was 
because the strains had been grown for some time on artificial media 
before the classification was made and virulence tests were carried out. 
Now that an antiserum for identification of this type is available it is 
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encountered.  An  antiserum  has  been  secured for this  type  by  the 
inoculation of a  horse. 
Type X.--Five  strains  from cases of pneumonia  are of this  type. 
All were from severe cases, three were fatal, two of which were shown 
to have positive blood cultures.  The  cultures were of moderate  or 
low  virulence  for mice.  An  homologous  rabbit  antiserum  had  500 
protective units per cc. while  a  polyvalent antibody preparation  for 
TABLE V. 
Grouting of Pneumococci of So Called Group IV. 
Types 
Type IV 
Type V 
Type VI 
• Type VII 
Type VIII 
Type IX 
Type X 
Type XI 
Type XII 
Type XIII 
Total strains typed 
Strains not typed 
Total strains 
Total  No. of 
strains in-  strains from 
cludlng  cases 
stock  1927-1928  strains* 
21  19 
8  6 
8  7 
11  11 
6  4 
6  6 
5  5 
4  4 
4  4 
4  4 
77  70 
50  50 
127  120 
Percentage 
of case 
stratus in 
each type 
15.8 
5.0 
5.8 
9.2 
3.3 
5.0 
4.2 
3.3 
3.3 
3.3 
58.3 
41.7 
100.0 
NO. Of 
deaths 
7 
2" 
2 
1 
1 
3 
1 
2 
0 
24 
11 
35 
Percentage 
of deaths 
in each type 
36.8 
83.3 
28.6 
18.2 
25.0 
16.7 
60.0 
25.0 
50.0 
0 
34.3 
22.0 
29.2 
No. of  cases 
having  posi. 
five  blood 
cultures 
5 
5 
2 
2 
1 
1 
2 
1 
2 
0 
21 
15 
36 
* Stock strains obtained from Dr. Avery,  of The Rockefeller Institute for Medical 
Research, Dr. Robinson, of the William H. Singer Memorial Research Laboratory, 
Pittsburg,  and  Dr.  John  ¥.  Sugg,  of  the  Vanderbilt  University,  Nashville, 
Tennessee. 
Types I,  II  and  III had  only 1  unit  agains  t  Type X.  The results 
indicate  that  in  therapy  this  type  also  must  be  considered  as  an 
entity. 
Type XI.--Four  strains from cases of pneumonia are of this type. 
One  patient  died.  Three cases  were rated  as  moderate in  severity 
and one of these had a positive blood culture.  Type XI strains have 
a  moderate tendency to hemolyze blood.  They were of moderate to 
high  virulence for mice  when  first isolated  and  lost  their virulence 
rapidly. 472  PNEUMOCOCCI GROUP IV 
A  rabbit immunized with a  representative of the type had 200  to 
500 protective units per cc. against the different strains classified as 
this type.  A  polyvalent antibody preparation  for Types I,  II  and 
IH had 1 to 5 protective units or less against Type XI strains. 
Type XII.--Four strains from cases of pneumonia are of this type. 
Three of the four cases were rated as severe and were shown to have 
positive blood  cultures.  Two of the cases were fatal.  The fourth 
case was moderately ill.  Type XII strains had moderate virulence 
for mice. 
Type XiII.--Four strains from cases of pneumonia are of this type. 
One case was rated as severe, three as moderate.  None of the cases 
were fatal.  These strains were of moderate virulence for mice when 
first isolated but rapidiy lost their virulence. 
The total number of strains studied, including the stock strains, the 
number from lobar pneumonia cases, the deaths with their percentages 
and  the  number of  positive  blood  cultures  are  given in  Table  V. 
Since the number of cases studied is comparatively small, the figures 
may be deceptive as to  the actual prevalence of the types and the 
mortality of the cases.  This is especially true in regard to the mortal- 
ity; as the infecting organism would be more easily isolated in pure 
culture from severe cases and would be grouped, while in the lightly 
infected cases it might not be recovered. 
Monovalent antiserums for each of the types were tested to find 
whether there was any protective power against representative strains 
of each of the other groups where strains of sufficient virulence were 
available.  These tests were made with the serum from immunized 
rabbits and very little protection was found, i.e., less than 1 unit per 
cc.  against  heterologous  strains.  Concentrated  Type  II  antibody 
preparations and concentrated polyvalent antibody preparations hav- 
ing a high potency against Type II were found to have 10 to 20 units 
against Types V and VI; an amount too low to ensure efficient treat- 
ment.  These  results  indicate  that  to  be  effective a  serum  should 
contain antibodies stimulated by a type similar to the infecting type. 
Protection experiments have shown that  monovalent antiserums of 
high protective value as determined by laboratory tests can be pre- 
pared for most of these types by inoculation of rabbits and horses and 
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present the work is not sufl~dently advanced to make a definite state- 
ment.  The final estimate of their value must be determined by the 
clinical use in the treatment of actual pneumonia cases. 
In a recent paper Park, Bullowa and Rosenbluth (11) with reference 
to  the  unfavorable  results  of  serum  treatment of  Type III  cases, 
discussed the difference in the ability of Type III antiserums to pro- 
tect against freshly isolated Type III strains as compared with old 
stock  strains.  The  almost  complete  failure  of  the  antiserums  to 
successfully combat freshly isolated strains is probably  due both to 
the low potency of the antiserum and to the remarkably large capsules 
which  these  organisms  develop.  The  stock  strains  have  smaller 
capsules, although they are "fully virulent" according to the definition 
which we have given above.  The Type III stock strains had a much 
greater antibody stimulating power than the freshly isolated strains. 
Thus an antiserum prepared with a  stock strain had 500 protective 
units against the stock Type III strains and 25 or less protective units 
against freshly isolated Type III strains, while an antiserum prepared 
with a freshly isolated strain had 5 units against the stock strain and 
considerably  less  than  1  unit  against  the  freshly  isolated  strains. 
None of the freshly isolated strains of Types IV to XIII  equalled 
Type III in the development of capsules, although there was consider- 
able difference among representative strains in regard to this tendency. 
All surpassed freshly isolated Type III strains in antibody stimulating 
power.  From these observations it is deduced that the new types are 
of a  nature which should be  susceptible to  the  action  of  suitable 
antiserums. 
It is evident that the preparation of so many different  type anti- 
serums and the determination of the infecting type and the carrying 
out  of  specific treatment,  while possible,  will be  a  very  laborious 
procedure.  It would be very much simplified, if suitable polyvaient 
antiserums  could be  prepared,  which would be  effective against  a 
large or considerable number of types and if a polyvalent antiserum 
could be used for identification of cases suitable for treatment.  We 
are studying the possibility of preparing such a therapeutic antiserum. 
Certain difficulties have already been encountered, in as much as, the 
potency for the separate types is lowered somewhat in proportion to 
the number of strains injected.  Possibly by  combining the refined 474  PNEUMOCOCCI GROUP IV 
and  concentrated  antiserums  of  horses  immunized  each  against  a 
few strains,  a  preparation can be obtained which will be sufficiently 
potent. 
SUMM'~kRy. 
The pneumococci hitherto known as Group IV have been separated 
into ten types which have been designated by Roman numerals from 
IV to XIII.  These have been correlated as far as possible with the 
types  described by  others.  The prevalence and mortality  of  cases 
due to each type have been estimated in the limited number of cases 
studied. 
Laboratory  tests indicated that  therapeutic antiserums for Types 
I,  II and III have very little protective power against  the recently 
separated types. 
Monovalent antiserums of high agglutinative and protective power 
were prepared in rabbits for each type. 
Several monovalent antiserums each specific for a  type, which are 
suitable for agglutination and experimental therapeutic use, have been 
obtained by immunizing horses. 
An antiserum prepared for one type had very little cross-protective 
power against other types. 
A  study of the possibility of preparing a  suitable refined and con- 
centrated polyvalent antiserum has been begun. 
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